{
    "Clinical Trial ID": "NCT00082641",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm I",
        "  Patients receive vaccination comprising p53-infected autologous dendritic cells subcutaneously (SC) 1 week after completion of doxorubicin and cyclophosphamide, 1 week after completion of paclitaxel (or after surgery for patients with stage III disease), and at 6 and 12 weeks after completion of radiotherapy (for a total of 4 vaccinations).",
        "  autologous dendritic cell-adenovirus p53 vaccine: Given subcutaneously on one of two schedules",
        "INTERVENTION 2: ",
        "  Arm II",
        "  Patients receive vaccination comprising p53-infected autologous dendritic cells SC at 6, 8, 10, and 12 weeks after completion of radiotherapy.",
        "  autologous dendritic cell-adenovirus p53 vaccine: Given subcutaneously on one of two schedules"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed invasive breast cancer meeting the following criteria:",
        "  Clinically locally advanced disease (stage III) with a primary tumor at least 4 cm by mammogram, ultrasound, or palpation AND/OR palpable axillary nodes larger than 1 cm",
        "  Planned neoadjuvant chemotherapy",
        "  p53-overexpressing tumor by immunohistochemistry",
        "  Delayed-type hypersensitivity to at least 1 of 3 standard antigens",
        "  Hormone receptor status:",
        "  Not specified",
        "  PATIENT CHARACTERISTICS:",
        "  Age",
        "  19 and over",
        "  Sex",
        "  Female",
        "  Menopausal status",
        "  Not specified",
        "  Performance status",
        "  ECOG 0-1",
        "  Life expectancy",
        "  Not specified",
        "  Hematopoietic",
        "  WBC > 4,000/mm^3",
        "  Platelet count > 100,000/mm^3",
        "  Hepatic",
        "  Bilirubin < 2 times upper limit of normal (ULN)",
        "  Hepatitis B surface antigen negative",
        "  Hepatitis C antibody negative",
        "  Renal",
        "  Creatinine < 2 times ULN",
        "  Immunologic",
        "  HIV negative",
        "  No prior or concurrent autoimmune disorder",
        "  Other",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective contraception during and for at least 6 months after study participation",
        "  No other concurrent illness that would preclude study participation",
        "  PRIOR CONCURRENT THERAPY:",
        "  Biologic therapy",
        "  Not specified",
        "  Chemotherapy",
        "  See Disease Characteristics",
        "  No prior chemotherapy",
        "  Endocrine therapy",
        "  Not specified",
        "  Radiotherapy",
        "  Not specified",
        "  Surgery",
        "  See Disease Characteristics",
        "  Other",
        "  No concurrent participation in another therapeutic clinical trial"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants Who Experienced Toxicity to the Vaccine",
        "  This outcome measure looks at the safety of the vaccine by documenting the number of grade 2, 3, or toxicities experienced by participants related to the vaccine.",
        "  Time frame: 1 week after each vaccine dose.",
        "Results 1: ",
        "  Arm/Group Title: Arm I",
        "  Arm/Group Description: Patients receive vaccination comprising p53-infected autologous dendritic cells subcutaneously (SC) 1 week after completion of doxorubicin and cyclophosphamide, 1 week after completion of paclitaxel (or after surgery for patients with stage III disease), and at 6 and 12 weeks after completion of radiotherapy (for a total of 4 vaccinations).",
        "  autologous dendritic cell-adenovirus p53 vaccine: Given subcutaneously on one of two schedules",
        "  Overall Number of Participants Analyzed: 11",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  0   0.0%",
        "Results 2: ",
        "  Arm/Group Title: Arm II",
        "  Arm/Group Description: Patients receive vaccination comprising p53-infected autologous dendritic cells SC at 6, 8, 10, and 12 weeks after completion of radiotherapy.",
        "  autologous dendritic cell-adenovirus p53 vaccine: Given subcutaneously on one of two schedules",
        "  Overall Number of Participants Analyzed: 12",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  0   0.0%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 5/11 (45.45%)",
        "  Nausea 1/11 (9.09%)",
        "  Vomiting 1/11 (9.09%)",
        "  Fever 1/11 (9.09%)",
        "  skin infection  [1]1/11 (9.09%)",
        "  Hip fracture 0/11 (0.00%)",
        "  Confusion 1/11 (9.09%)",
        "Adverse Events 2:",
        "  Total: 1/12 (8.33%)",
        "  Nausea 0/12 (0.00%)",
        "  Vomiting 0/12 (0.00%)",
        "  Fever 0/12 (0.00%)",
        "  skin infection  [1]0/12 (0.00%)",
        "  Hip fracture 1/12 (8.33%)",
        "  Confusion 0/12 (0.00%)"
    ]
}